AI-generated summary
In this randomized, double-blind phase III study, head-and-neck cancer patients receiving chemoradiotherapy were given either low-level laser therapy or a placebo laser before each radiation session. The authors report that laser therapy did not significantly reduce severe oral mucositis, though it was associated with fewer radiation interruptions due to mucositis. The study enrolled 75 patients, and the authors note a marginal benefit could not be excluded.
- Participants
- 75
- Who or what was studied
- Patients with squamous cell or undifferentiated carcinoma of the oral cavity, pharynx, larynx, or neck metastases of unknown primary, receiving concurrent chemoradiotherapy with cisplatin
- Limits stated in the abstract
- The abstract reports that the primary endpoint of reducing severe mucositis was not met and that a marginal benefit could not be excluded, and the sample was sized for a specific anticipated effect.
Written by an AI model from this paper’s abstract only and checked automatically against it, but it can still be wrong. It is not medical advice. Read the full paper. See the editorial policy.
Abstract
The full abstract is not shown here because it is protected by the publisher’s copyright. Read it on linkinghub.elsevier.com.
Record from PubMed, a service of the National Library of Medicine.
How to read a trial: what to check before relying on this kind of research.
Terms in this paper: Oral mucositis, Laser, Low-level laser therapy, GRADE, Dose. Each links to its definition in the glossary.
A summary of published research, not medical advice. One study rarely settles a question. See the disclaimer and how to read research.